Cargando…
Correction to: A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol
Autores principales: | Li, Chen, Wang, Xiaomin, Wang, Xin, Han, Chun, Wang, Ping, Pang, Qingsong, Chen, Junqiang, Sun, Xinchen, Wang, Lan, Zhang, Wencheng, Lin, Yu, Ge, Xiaolin, Zhou, Zongmei, Ni, Wenjie, Chang, Xiao, Liang, Jun, Deng, Lei, Wang, Wenqing, Zhao, Yidian, Xiao, Zefen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533695/ https://www.ncbi.nlm.nih.gov/pubmed/31122185 http://dx.doi.org/10.1186/s12885-019-5699-9 |
Ejemplares similares
-
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol
por: Li, Chen, et al.
Publicado: (2019) -
Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A)
por: Wang, Lan, et al.
Publicado: (2021) -
Does chemoradiotherapy benefit elderly patients with esophageal squamous cell cancer? A propensity-score matched analysis on multicenter data (3JECROG R-03A)
por: Chen, Mingqiu, et al.
Publicado: (2020) -
Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03)
por: Zhang, Wencheng, et al.
Publicado: (2020) -
A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol
por: Gao, Lin-rui, et al.
Publicado: (2020)